SNSE logo

SNSE
Sensei Biotherapeutics Inc

2,662
Mkt Cap
$23.55M
Volume
21,119.00
52W High
$36.76
52W Low
$5.31
PE Ratio
-0.93
SNSE Fundamentals
Price
$17.79
Prev Close
$17.56
Open
$18.47
50D MA
$27.53
Beta
0.87
Avg. Volume
37,819.16
EPS (Annual)
-$16.72
P/B
0.98
Rev/Employee
$0.00
$6.22
Loading...
Loading...
News
all
press releases
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. The first quarter of 2026 was...
News Placeholder
More News
News Placeholder
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient was dosed in Study FTH-PIK-101 (NCT07558733), a Phase 1b/2 trial of PIKTOR...
News Placeholder
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16th, 2026 at 12:45 p.m...
News Placeholder
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the full year ended December 31, 2025, following its previously announced acquisition of Faeth Therapeutics and...
News Placeholder
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on March 11, 2026, Senseis Board of Directors granted a new employee an option to purchase 166,435 shares of the Companys...
News Placeholder
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Senseis Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893...
News Placeholder
Small Cap Stocks To Add to Your Watchlist - February 18th
Rackspace Technology, Direxion Daily PLTR Bear 1X Shares, Spring Valley Acquisition, Direxion Daily MU Bull 2X Shares, Sensei Biotherapeutics, Inflection Point Acquisition Corp. II, and Direxion...
News Placeholder
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition
The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.
News Placeholder
Sensei Biotherapeutics Stock Soars 230% After Faeth Deal
SNSE up on acquisition of Faeth Therapeutics, $200M private placement, and addition of PIKTOR to pipeline targeting cancer.read more...
News Placeholder
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. (Faeth), a clinical-stage biotechnology company developing multi-node therapies that target...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available